DilenyTech, an e-health Egyptian startup just secured a $160,000 non-equity grant that will enhance its AI platform when expediting the detection of breast cancer. DilenyTech was founded in 2018 the startup plans to revolutionize the screening and diagnosis of groundbreaking AI assistance to create a precise diagnosis and accelerating reporting.
The fund was received by the Information Technology Academia Collaboration (ITAC) program that is affiliated with the Information Technology Industry Development Agency (ITIDA). This comes several months after the creation of a US-based patent for a novel AI-enabled image analysis system.
Dr. Ahmed Ehab Mahmoud, the CEO, and founder detailed how thousands of healthcare professionals can access their online platform “anytime/anywhere.” DilenyTech comes up with solutions that touch on breast cancer risk assessment, medical imaging analysis, and structured reporting of medical applications. Thus far, the startup has offered its services to top-tier international health technology firms with users spread across 3 continents.
The team combines over 15 years of scientific and professional experience, having completed over 90 publications and 3 U.S patients. DilenyTech LLC is one of the fastest-growing e-health startups in Africa and MENA regions specialized in medical imaging analysis and AI.
Awards & achievements
DilenyTech qualified in the 2nd rank of the Decoding Health Challenge that was organized by Health 2.0 Egypt and UNESCO in 2019. DilenyTech was one of Baobab Insight’s top 50 AI startups to watch in 2020 Africa.
DilenyTech created the first worldwide bi-lingual AI-enabled breast cancer risk assessment tool in English and Arabic. The startup developed vendor-neutral technology delivering ultrasound imaging.
More on: Wamda